Please Wait
Applying Filters...
menu
    • menu
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Veranova: A CDMO that manages complexity with confidence.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    Gangwal Healthcare is powered by innovation, driving health, wellness & healing.

    Virtual Booth

    Contact Supplier

    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Bictegravir

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 7Biktarvy

    02 5Descovy

    03 5Genvoya

    04 5Odefsey

    05 2Revenue share - Symtuza

    06 2Symtuza

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Symtuza

    Bictegravir, Emtricitabine, Tenofovir Alafenamide

    arrow
    CPhI Japan
    Not Confirmed

    Brand Name : Symtuza

    U.S.A
    arrow
    CPhI Japan
    Not Confirmed

    Gilead

    Bictegravir, Emtricitabine, Tenofovir Alafenamide

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2020 Revenue in Millions : 488

    2019 Revenue in Millions : 379

    Growth (%) : 29

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Descovy

    Bictegravir, Emtricitabine, Tenofovir Alafenamide

    arrow
    CPhI Japan
    Not Confirmed

    Brand Name : Descovy

    U.S.A
    arrow
    CPhI Japan
    Not Confirmed

    Gilead

    Bictegravir, Emtricitabine, Tenofovir Alafenamide

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2020 Revenue in Millions : 1,861

    2019 Revenue in Millions : 1,500

    Growth (%) : 24

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Odefsey

    Bictegravir, Emtricitabine, Tenofovir Alafenamide

    arrow
    CPhI Japan
    Not Confirmed

    Brand Name : Odefsey

    U.S.A
    arrow
    CPhI Japan
    Not Confirmed

    Gilead

    Bictegravir, Emtricitabine, Tenofovir Alafenamide

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2020 Revenue in Millions : 1,672

    2019 Revenue in Millions : 1,655

    Growth (%) : 1

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Biktarvy

    Bictegravir, Emtricitabine, Tenofovir Alafenamide

    arrow
    CPhI Japan
    Not Confirmed

    Brand Name : Biktarvy

    U.S.A
    arrow
    CPhI Japan
    Not Confirmed

    Gilead

    Bictegravir, Emtricitabine, Tenofovir Alafenamide

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2020 Revenue in Millions : 7,259

    2019 Revenue in Millions : 4,738

    Growth (%) : 53

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Genvoya

    Bictegravir, Emtricitabine, Tenofovir Alafenamide

    arrow
    CPhI Japan
    Not Confirmed

    Brand Name : Genvoya

    U.S.A
    arrow
    CPhI Japan
    Not Confirmed

    Gilead

    Bictegravir, Emtricitabine, Tenofovir Alafenamide

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2020 Revenue in Millions : 3,338

    2019 Revenue in Millions : 3,931

    Growth (%) : -15

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Biktarvy

    Bictegravir, Emtricitabine, Tenofovir Alafenamide

    arrow
    CPhI Japan
    Not Confirmed

    Brand Name : Biktarvy

    U.S.A
    arrow
    CPhI Japan
    Not Confirmed

    Gilead

    Bictegravir, Emtricitabine, Tenofovir Alafenamide

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2021 Revenue in Millions : 8,624

    2020 Revenue in Millions : 7,259

    Growth (%) : 19

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Odefsey

    Bictegravir, Emtricitabine, Tenofovir Alafenamide

    arrow
    CPhI Japan
    Not Confirmed

    Brand Name : Odefsey

    U.S.A
    arrow
    CPhI Japan
    Not Confirmed

    Gilead

    Bictegravir, Emtricitabine, Tenofovir Alafenamide

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2021 Revenue in Millions : 1,568

    2020 Revenue in Millions : 1,672

    Growth (%) : -6

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Descovy

    Bictegravir, Emtricitabine, Tenofovir Alafenamide

    arrow
    CPhI Japan
    Not Confirmed

    Brand Name : Descovy

    U.S.A
    arrow
    CPhI Japan
    Not Confirmed

    Gilead

    Bictegravir, Emtricitabine, Tenofovir Alafenamide

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2021 Revenue in Millions : 1,700

    2020 Revenue in Millions : 1,861

    Growth (%) : -9

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Genvoya

    Bictegravir, Emtricitabine, Tenofovir Alafenamide

    arrow
    CPhI Japan
    Not Confirmed

    Brand Name : Genvoya

    U.S.A
    arrow
    CPhI Japan
    Not Confirmed

    Gilead

    Bictegravir, Emtricitabine, Tenofovir Alafenamide

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2021 Revenue in Millions : 2,879

    2020 Revenue in Millions : 3,338

    Growth (%) : -14

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Brand Name : Symtuza

    Bictegravir, Emtricitabine, Tenofovir Alafenamide

    arrow
    CPhI Japan
    Not Confirmed

    Brand Name : Symtuza

    U.S.A
    arrow
    CPhI Japan
    Not Confirmed

    Gilead

    Bictegravir, Emtricitabine, Tenofovir Alafenamide

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2021 Revenue in Millions : 531

    2020 Revenue in Millions : 488

    Growth (%) : 9

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.